Genetics, behavior, and brain dopamine systems

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Even for the reader unfamiliar with the topic of this chapter but familiar with dopamine and behavior, it is obvious that the topic of genes, behavior and brain dopamine systems cannot be covered in detail. Rather, the goal of the chapter is to provide the reader with an introduction and some examples, largely extracted from work in the authors’ laboratories. Previous reviews (Hitzemann et al., 1995; Hitzemann, 1998) can be referenced for important background material. The focus of this chapter will be largely on D2 dopamine receptors. The reasons for this emphasis include the longstanding emphasis on D2 receptors in the etiology and/or expression of a variety of behaviors including schizophrenia, substance abuse and alcoholism (Hitzemann, 1998). The other reason for this emphasis is the amazing variability among individuals in D2 receptor density and in the response to drugs which either stimulate or block these receptors. The reasons for this variability remain unclear, but there is ample evidence to suggest that genetic factors have an important role. Here we provide a clinical example to illustrate the variation in receptor density and drug response. Twenty-three normal controls were administered 0.5 mg/kg of methylphenidate iv. after being told they would receive either placebo or methylphenidate; behavioral effects were measured before and after the injection and included self-ratings of pleasant and unpleasant drug effects. On another day, the subjects were scanned for D2/D3 receptor density using positron emission tomography (PET) and 11C-raclopride as the ligand. Twelve of the 23 subjects (52%) reported the drug effects as very pleasant, 9 subjects (39%) reported the drug effects as unpleasant and 2 subjects (9%) reported no marked behavioral effects (Volkow et al., 1999). Importantly, the individuals who reported the drug effects as pleasant had lower levels of D2 receptor availability when compared with the “unpleasant” group (Figure 25.1). Although the average difference was small (20%), it was similar to the persistent differences reported between normal controls and withdrawn chronic alcoholics, cocaine, methamphetamine and heroin addicts (see, e.g., Volkow et al. 1993). These differences were nominally thought to be associated with receptor down-regulation as a result of drug-induced dopamine release. However, the data described in Figure 25.1 suggest that low D2 receptor availability could be a risk factor for drug abuse since presumably, the “pleasant” group would be more likely to try the drug again. The data in Figure 25.1 also illustrate that in this sample the range of D2 receptor availability was more than 100%. For other clinical samples, including postmortem samples, the range of D2 receptor availability has been similar and in some cases even greater (Hitzemann et al., 1998).

Original languageEnglish (US)
Title of host publicationNeurobehavioral Genetics
Subtitle of host publicationMethods and Applications, Second Edition
PublisherCRC Press
Pages371-388
Number of pages18
ISBN (Electronic)9781420003567
ISBN (Print)084931903X, 9780849319037
StatePublished - Jan 1 2006

Fingerprint

Dopamine
Brain
Pharmaceutical Preparations
Methylphenidate
Availability
Substance-Related Disorders
Raclopride
Drug Receptors
Dopamine Agents
Dopamine D2 Receptors
Methamphetamine
Heroin
Alcoholics
Cocaine
Positron-Emission Tomography
Alcoholism
Genetics
Schizophrenia
Positron emission tomography
Down-Regulation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hitzemann, R., McWeeney, S., & Belknap, J. (2006). Genetics, behavior, and brain dopamine systems. In Neurobehavioral Genetics: Methods and Applications, Second Edition (pp. 371-388). CRC Press.

Genetics, behavior, and brain dopamine systems. / Hitzemann, Robert; McWeeney, Shannon; Belknap, John.

Neurobehavioral Genetics: Methods and Applications, Second Edition. CRC Press, 2006. p. 371-388.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hitzemann, R, McWeeney, S & Belknap, J 2006, Genetics, behavior, and brain dopamine systems. in Neurobehavioral Genetics: Methods and Applications, Second Edition. CRC Press, pp. 371-388.
Hitzemann R, McWeeney S, Belknap J. Genetics, behavior, and brain dopamine systems. In Neurobehavioral Genetics: Methods and Applications, Second Edition. CRC Press. 2006. p. 371-388
Hitzemann, Robert ; McWeeney, Shannon ; Belknap, John. / Genetics, behavior, and brain dopamine systems. Neurobehavioral Genetics: Methods and Applications, Second Edition. CRC Press, 2006. pp. 371-388
@inbook{0121e8369e734d60b513356a27ff6a54,
title = "Genetics, behavior, and brain dopamine systems",
abstract = "Even for the reader unfamiliar with the topic of this chapter but familiar with dopamine and behavior, it is obvious that the topic of genes, behavior and brain dopamine systems cannot be covered in detail. Rather, the goal of the chapter is to provide the reader with an introduction and some examples, largely extracted from work in the authors’ laboratories. Previous reviews (Hitzemann et al., 1995; Hitzemann, 1998) can be referenced for important background material. The focus of this chapter will be largely on D2 dopamine receptors. The reasons for this emphasis include the longstanding emphasis on D2 receptors in the etiology and/or expression of a variety of behaviors including schizophrenia, substance abuse and alcoholism (Hitzemann, 1998). The other reason for this emphasis is the amazing variability among individuals in D2 receptor density and in the response to drugs which either stimulate or block these receptors. The reasons for this variability remain unclear, but there is ample evidence to suggest that genetic factors have an important role. Here we provide a clinical example to illustrate the variation in receptor density and drug response. Twenty-three normal controls were administered 0.5 mg/kg of methylphenidate iv. after being told they would receive either placebo or methylphenidate; behavioral effects were measured before and after the injection and included self-ratings of pleasant and unpleasant drug effects. On another day, the subjects were scanned for D2/D3 receptor density using positron emission tomography (PET) and 11C-raclopride as the ligand. Twelve of the 23 subjects (52{\%}) reported the drug effects as very pleasant, 9 subjects (39{\%}) reported the drug effects as unpleasant and 2 subjects (9{\%}) reported no marked behavioral effects (Volkow et al., 1999). Importantly, the individuals who reported the drug effects as pleasant had lower levels of D2 receptor availability when compared with the “unpleasant” group (Figure 25.1). Although the average difference was small (20{\%}), it was similar to the persistent differences reported between normal controls and withdrawn chronic alcoholics, cocaine, methamphetamine and heroin addicts (see, e.g., Volkow et al. 1993). These differences were nominally thought to be associated with receptor down-regulation as a result of drug-induced dopamine release. However, the data described in Figure 25.1 suggest that low D2 receptor availability could be a risk factor for drug abuse since presumably, the “pleasant” group would be more likely to try the drug again. The data in Figure 25.1 also illustrate that in this sample the range of D2 receptor availability was more than 100{\%}. For other clinical samples, including postmortem samples, the range of D2 receptor availability has been similar and in some cases even greater (Hitzemann et al., 1998).",
author = "Robert Hitzemann and Shannon McWeeney and John Belknap",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
isbn = "084931903X",
pages = "371--388",
booktitle = "Neurobehavioral Genetics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Genetics, behavior, and brain dopamine systems

AU - Hitzemann, Robert

AU - McWeeney, Shannon

AU - Belknap, John

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Even for the reader unfamiliar with the topic of this chapter but familiar with dopamine and behavior, it is obvious that the topic of genes, behavior and brain dopamine systems cannot be covered in detail. Rather, the goal of the chapter is to provide the reader with an introduction and some examples, largely extracted from work in the authors’ laboratories. Previous reviews (Hitzemann et al., 1995; Hitzemann, 1998) can be referenced for important background material. The focus of this chapter will be largely on D2 dopamine receptors. The reasons for this emphasis include the longstanding emphasis on D2 receptors in the etiology and/or expression of a variety of behaviors including schizophrenia, substance abuse and alcoholism (Hitzemann, 1998). The other reason for this emphasis is the amazing variability among individuals in D2 receptor density and in the response to drugs which either stimulate or block these receptors. The reasons for this variability remain unclear, but there is ample evidence to suggest that genetic factors have an important role. Here we provide a clinical example to illustrate the variation in receptor density and drug response. Twenty-three normal controls were administered 0.5 mg/kg of methylphenidate iv. after being told they would receive either placebo or methylphenidate; behavioral effects were measured before and after the injection and included self-ratings of pleasant and unpleasant drug effects. On another day, the subjects were scanned for D2/D3 receptor density using positron emission tomography (PET) and 11C-raclopride as the ligand. Twelve of the 23 subjects (52%) reported the drug effects as very pleasant, 9 subjects (39%) reported the drug effects as unpleasant and 2 subjects (9%) reported no marked behavioral effects (Volkow et al., 1999). Importantly, the individuals who reported the drug effects as pleasant had lower levels of D2 receptor availability when compared with the “unpleasant” group (Figure 25.1). Although the average difference was small (20%), it was similar to the persistent differences reported between normal controls and withdrawn chronic alcoholics, cocaine, methamphetamine and heroin addicts (see, e.g., Volkow et al. 1993). These differences were nominally thought to be associated with receptor down-regulation as a result of drug-induced dopamine release. However, the data described in Figure 25.1 suggest that low D2 receptor availability could be a risk factor for drug abuse since presumably, the “pleasant” group would be more likely to try the drug again. The data in Figure 25.1 also illustrate that in this sample the range of D2 receptor availability was more than 100%. For other clinical samples, including postmortem samples, the range of D2 receptor availability has been similar and in some cases even greater (Hitzemann et al., 1998).

AB - Even for the reader unfamiliar with the topic of this chapter but familiar with dopamine and behavior, it is obvious that the topic of genes, behavior and brain dopamine systems cannot be covered in detail. Rather, the goal of the chapter is to provide the reader with an introduction and some examples, largely extracted from work in the authors’ laboratories. Previous reviews (Hitzemann et al., 1995; Hitzemann, 1998) can be referenced for important background material. The focus of this chapter will be largely on D2 dopamine receptors. The reasons for this emphasis include the longstanding emphasis on D2 receptors in the etiology and/or expression of a variety of behaviors including schizophrenia, substance abuse and alcoholism (Hitzemann, 1998). The other reason for this emphasis is the amazing variability among individuals in D2 receptor density and in the response to drugs which either stimulate or block these receptors. The reasons for this variability remain unclear, but there is ample evidence to suggest that genetic factors have an important role. Here we provide a clinical example to illustrate the variation in receptor density and drug response. Twenty-three normal controls were administered 0.5 mg/kg of methylphenidate iv. after being told they would receive either placebo or methylphenidate; behavioral effects were measured before and after the injection and included self-ratings of pleasant and unpleasant drug effects. On another day, the subjects were scanned for D2/D3 receptor density using positron emission tomography (PET) and 11C-raclopride as the ligand. Twelve of the 23 subjects (52%) reported the drug effects as very pleasant, 9 subjects (39%) reported the drug effects as unpleasant and 2 subjects (9%) reported no marked behavioral effects (Volkow et al., 1999). Importantly, the individuals who reported the drug effects as pleasant had lower levels of D2 receptor availability when compared with the “unpleasant” group (Figure 25.1). Although the average difference was small (20%), it was similar to the persistent differences reported between normal controls and withdrawn chronic alcoholics, cocaine, methamphetamine and heroin addicts (see, e.g., Volkow et al. 1993). These differences were nominally thought to be associated with receptor down-regulation as a result of drug-induced dopamine release. However, the data described in Figure 25.1 suggest that low D2 receptor availability could be a risk factor for drug abuse since presumably, the “pleasant” group would be more likely to try the drug again. The data in Figure 25.1 also illustrate that in this sample the range of D2 receptor availability was more than 100%. For other clinical samples, including postmortem samples, the range of D2 receptor availability has been similar and in some cases even greater (Hitzemann et al., 1998).

UR - http://www.scopus.com/inward/record.url?scp=78149359701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149359701&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:78149359701

SN - 084931903X

SN - 9780849319037

SP - 371

EP - 388

BT - Neurobehavioral Genetics

PB - CRC Press

ER -